肝动脉灌注化疗联合瑞戈非尼治疗结直肠癌肝转移患者的临床研究  

Clinical trial of hepatic arterial infusion chemotherapy combined with regorafenib in the treatment of patients with liver metastasis of colorectal cancer

作　　者：彭涛[1] 杨沔[1] 金梁斌 沈雷斌 PENG Tao;YANG Mian;JIN Liang-bin;SHEN Lei-bin(Colorectal and Anorectal Surgery Department,Ningbo Medical Center Li Huili Hospital,Ningbo 315000,Zhejiang Province,China)

机构地区：[1]宁波市医疗中心李惠利医院结直肠肛肠外科,浙江宁波315000

出　　处：《中国临床药理学杂志》2024年第2期185-189,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察肝动脉灌注化疗(HAIC)联合瑞戈非尼治疗结直肠癌肝转移的近远期效果。方法入选结直肠癌肝转移患者作为研究对象,按队列法分为试验组和对照组。对照组采用mFOLFOX6的HAIC化疗方案,试验组在对照组的基础上第1~21 d联合口服瑞戈非尼160 mg治疗,28 d为1个周期。治疗28 d后评价近期疗效,比较2组患者肿瘤标志物、肝功能、远期疗效、药物不良反应。结果试验组入组38例和对照组入组42例。试验组和对照组的客观缓解率分别为26.32%和9.52%,疾病控制率分别为71.05%和47.62%,治疗后,试验组和对照组的血清癌胚抗原水平分别为(10.06±2.33)和(14.67±3.50)μg·L^(-1),糖类抗原199水平分别为(41.39±10.25)和(62.19±15.38)kU·L^(-1),糖类抗原242水平分别为(8.67±2.12)和(13.04±3.17)kU·L^(-1),血清糖类抗原125水平分别为(36.52±9.18)和(45.22±9.01)kU·L^(-1),血清谷草转氨酶水平分别为(26.44±6.72)和(33.17±8.20)U·L^(-1),谷丙转氨酶水平分别为(22.98±5.78)和(30.89±7.62)U·L^(-1),中位无进展生存期分别为3.7和2.7个月,中位总生存期分别为11.7和9.4个月。试验组上述指标与对照组比较,在统计学上差异均有统计学意义(均P<0.05)。试验组和对照组的总药物不良反应发生率分别为76.32%和59.52%,在统计学上差异无统计学意义(P>0.05)。结论HAIC联合瑞戈非尼治疗结直肠癌肝转移显著提高近期疗效,延长患者生存期,临床获益较好。Objective To observe the short-term and long-term effects of hepatic artery infusion chemotherapy(HAIC)combined with regorafenib in the treatment of liver metastasis from colorectal cancer.Methods Patients with liver metastasis from colorectal cancer were reviewed.They were divided into treatment group and control group according to cohort method.The control group was treated with mFOLFOX6 HAIC chemotherapy regimen,and the experimental group was treated with 160 mg of regorafenib orally on the 1st to 21st day on the basis of the control group,28 days as a cycle.After 28 days of treatment,the short-term efficacy was evaluated.Tumor markers,liver function,long-term efficacy,and adverse drug reactions in the two groups were compared.Results There were 38 cases in the treatment group and 42 cases in the control group.The objective response rates of the treatment gro up and the control group were 26.32%and 9.52%;the disease control rates were 71.05%and 47.62%.After treatment,the levels of carcinoembryonic antigen in these two groups were(10.06±2.33)and(14.67±3.50)μg·L^(-1);the levels of carbohydrate antigen 199 in these two groups were(41.39±10.25)and(62.19±15.38)kU·L^(-1);the levels of carbohydrate antigen 242 in these two groups were(8.67±2.12)and(13.04±3.17)kU·L^(-1);the serum carbohydrate antigen 125 levels of these two groups were(36.52±9.18)and(45.22±9.01)kU·L^(-1).After treatment,the serum glutamic-oxalacetic transaminase levels in these two groups were(26.44±6.72)and(33.17±8.20)U·L^(-1);the levels of glutamic pyruvic transaminase in these two groups were(22.98±5.78)and(30.89±7.62)U·L^(-1).The median progression free survival time of these two groups was 3.7 and 2.7 months;the median overall survival time of these two groups was 11.7 and 9.4 months.The difference of the obove indicators between the treatment group and the control group were statistically significant(P<0.05).The total incidence of adverse drug reactions in the treatment group and control group were 76.32%and 59.52%,with no sta

关 键 词：瑞戈非尼 肝动脉灌注化疗 结直肠癌 肝转移 疗效 肿瘤标志物 

分 类 号：R979.1[医药卫生—药品]